UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Clinical trials for UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could adding durvalumab early beat lung cancer?
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation (and continuing it afterward) helps people with stage 3 lung cancer that can't be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagnosed…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
New combo therapy aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase study tests the safety and best dose of adding minnelide to the standard drug osimertinib for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if the combination can better control tumor growth. About 8 adults with adv…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
Experimental combo aims to boost Radiation's punch against returning lung tumors
Disease control OngoingThis early-phase study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be removed by surgery. The main goals are to find the safest dose…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
New combo therapy targets tough lung cancers in Biomarker-Guided trial
Disease control OngoingThis study tests a combination of two drugs, trametinib and pembrolizumab, in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see how well this treatment works based on specific genetic markers in each patient's tumor. About 37 particip…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Cancer vaccine plus immunotherapy shows promise in advanced lung and Head/Neck tumors
Disease control OngoingThis study tests a combination of the CIMAvax vaccine (which targets a protein that helps tumors grow) and nivolumab (an immunotherapy that boosts the immune system) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best …
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo therapy shows promise for tough lung cancers
Disease control OngoingThis early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The study includes 21 participants and aims…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New combo aims to shrink lung tumors when immunotherapy fails
Disease control OngoingThis study tests a new drug, pevonedistat, combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has already been treated with immunotherapy. The goal is to see if this combination can shrink tumors or stop them f…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:17 UTC